257 related articles for article (PubMed ID: 31152785)
1. Novel therapeutic strategies for spinal osteosarcomas.
Anwar MA; El-Baba C; Elnaggar MH; Elkholy YO; Mottawea M; Johar D; Al Shehabi TS; Kobeissy F; Moussalem C; Massaad E; Omeis I; Darwiche N; Eid AH
Semin Cancer Biol; 2020 Aug; 64():83-92. PubMed ID: 31152785
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and senescence in the immune microenvironment of osteosarcoma: focus on new therapeutic strategies.
Ying H; Li ZQ; Li MP; Liu WC
Front Endocrinol (Lausanne); 2023; 14():1217669. PubMed ID: 37497349
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for osteosarcoma: Where do we go from here?
Wedekind MF; Wagner LM; Cripe TP
Pediatr Blood Cancer; 2018 Sep; 65(9):e27227. PubMed ID: 29923370
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic vaccines and immune checkpoints inhibition options for gynecological cancers.
Di Tucci C; Schiavi MC; Faiano P; D'Oria O; Prata G; Sciuga V; Giannini A; Palaia I; Muzii L; Benedetti Panici P
Crit Rev Oncol Hematol; 2018 Aug; 128():30-42. PubMed ID: 29958629
[TBL] [Abstract][Full Text] [Related]
5. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
6. [Primary spinal osteosarcomas].
Khalfallah M; Malca S; Roche PH; Duffaud F; Soumare O; Garbe L; Pellet W
Neurochirurgie; 1997; 43(1):28-34. PubMed ID: 9205624
[TBL] [Abstract][Full Text] [Related]
7. Progress and opportunities for immune therapeutics in osteosarcoma.
Lettieri CK; Appel N; Labban N; Lussier DM; Blattman JN; Hingorani P
Immunotherapy; 2016 Oct; 8(10):1233-44. PubMed ID: 27605071
[TBL] [Abstract][Full Text] [Related]
8. The Osteosarcoma Microenvironment: A Complex But Targetable Ecosystem.
Corre I; Verrecchia F; Crenn V; Redini F; Trichet V
Cells; 2020 Apr; 9(4):. PubMed ID: 32326444
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs.
Chen C; Xie L; Ren T; Huang Y; Xu J; Guo W
Cancer Lett; 2021 Mar; 500():1-10. PubMed ID: 33359211
[TBL] [Abstract][Full Text] [Related]
10. Osteosarcoma, personalized medicine, and tissue engineering; an overview of overlapping fields of research.
Bozorgi A; Sabouri L
Cancer Treat Res Commun; 2021; 27():100324. PubMed ID: 33517237
[TBL] [Abstract][Full Text] [Related]
11. Innate Immune Cells: A Potential and Promising Cell Population for Treating Osteosarcoma.
Wang Z; Wang Z; Li B; Wang S; Chen T; Ye Z
Front Immunol; 2019; 10():1114. PubMed ID: 31156651
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin Overrides Osteosarcoma Differentiative Block and Reprograms the Tumor Immune Environment Enabling Effective Combination with Immune Checkpoint Inhibitors.
Ratti C; Botti L; Cancila V; Galvan S; Torselli I; Garofalo C; Manara MC; Bongiovanni L; Valenti CF; Burocchi A; Parenza M; Cappetti B; Sangaletti S; Tripodo C; Scotlandi K; Colombo MP; Chiodoni C
Clin Cancer Res; 2017 Sep; 23(17):5149-5161. PubMed ID: 28600479
[No Abstract] [Full Text] [Related]
14. A Review of T-Cell Related Therapy for Osteosarcoma.
Yoshida K; Okamoto M; Aoki K; Takahashi J; Saito N
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664248
[TBL] [Abstract][Full Text] [Related]
15. The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma.
Wang SD; Li HY; Li BH; Xie T; Zhu T; Sun LL; Ren HY; Ye ZM
Int Immunopharmacol; 2016 Sep; 38():81-9. PubMed ID: 27258185
[TBL] [Abstract][Full Text] [Related]
16. The immunotherapy of canine osteosarcoma: a historical and systematic review.
Wycislo KL; Fan TM
J Vet Intern Med; 2015; 29(3):759-69. PubMed ID: 25929293
[TBL] [Abstract][Full Text] [Related]
17. Applying Osteosarcoma Immunology to Understand Disease Progression and Assess Immunotherapeutic Response.
Pratt HG; Justin EM; Lindsey BA
Adv Exp Med Biol; 2020; 1258():91-109. PubMed ID: 32767236
[TBL] [Abstract][Full Text] [Related]
18. The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer.
van Dijk N; Funt SA; Blank CU; Powles T; Rosenberg JE; van der Heijden MS
Eur Urol; 2019 Mar; 75(3):435-444. PubMed ID: 30274701
[TBL] [Abstract][Full Text] [Related]
19. Survival of patients with malignant primary osseous spinal neoplasms: results from the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2003.
Mukherjee D; Chaichana KL; Gokaslan ZL; Aaronson O; Cheng JS; McGirt MJ
J Neurosurg Spine; 2011 Feb; 14(2):143-50. PubMed ID: 21184634
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors: The linchpins of modern immunotherapy.
Wilky BA
Immunol Rev; 2019 Jul; 290(1):6-23. PubMed ID: 31355494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
